Cialis (Tadalafil) in Children Under 12: What Pediatric Off-Label Use Actually Looks Like

Why Tadalafil Is Used Off-Label in Young Children

Tadalafil is not FDA-approved for children under 12, but pediatric PAH is a life-threatening condition with few approved options. Clinicians prescribe tadalafil off-label in this age group because the drug's mechanism, inhibiting PDE5 to raise cyclic GMP and relax pulmonary vascular smooth muscle, is disease-relevant regardless of age, and waiting for full pediatric approval could cost a child years of untreated or under-treated disease.

The Regulatory Gap

The FDA approved tadalafil (Adcirca 40 mg) for PAH in adults in 2009, based largely on the PHIRST trial (N=405) [1]. Pediatric approval was later extended downward, but not to the under-12 bracket as a distinct labeled population. The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to study drugs in pediatric populations, yet specific sub-age carve-outs persist when trial enrollment is difficult [2].

This means a 7-year-old with idiopathic PAH is not covered by any tadalafil label, yet their pulmonologist may still write the prescription under off-label practice standards that the FDA explicitly permits for licensed physicians [2].

PAH in Young Children: The Clinical Burden

Pediatric PAH carries a median survival measured in years without treatment. The most recent registry data from the TOPP (Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension) study found that children under 3 years had the worst hemodynamic profiles at diagnosis, with mean pulmonary arterial pressure exceeding 50 mmHg in a significant subset [3]. Sildenafil (another PDE5 inhibitor) has been used longer in this age group, but tadalafil's once-daily dosing is a practical advantage for families managing a complex medication regimen.

What the Clinical Trial Evidence Actually Shows

The controlled data for tadalafil in children under 12 are sparse but not absent. Extrapolation from adolescent and mixed-age pediatric trials forms the basis of most dosing decisions in this age group.

The TEMPO Trial

The most cited pediatric tadalafil dataset comes from TEMPO (Tadalafil in children with pulmonary arterial hypertension), a phase 2, open-label, dose-ranging trial that enrolled patients aged 2 to 17 years [4]. The trial tested doses of 0.5 mg/kg/day, 1 mg/kg/day, and 2.5 mg/kg/day (capped at 40 mg/day).

Key findings from TEMPO included:

• The 1 mg/kg/day dose produced the most favorable balance of efficacy signal and tolerability.
• At 24 weeks, the 1 mg/kg/day group showed a mean reduction in pulmonary vascular resistance index of approximately 25% from baseline.
• Adverse events were consistent with those seen in adults: headache, flushing, and nasopharyngitis were most common [4].

Children under 6 were enrolled in TEMPO, but the sub-group data for under-12s specifically were not powered to draw definitive conclusions.

Sildenafil Comparison and the STARTS-2 Warning

Sildenafil, tadalafil's chemical cousin in the PDE5 class, received FDA approval for pediatric PAH (1 to 17 years) and was then the subject of a Black Box Warning update after STARTS-2 showed increased mortality in children receiving higher sildenafil doses over long-term follow-up [5]. The FDA stated in its 2012 safety communication that high-dose sildenafil should not be used in children aged 1 to 17 years [5].

This warning did not apply to tadalafil directly, but it raised appropriate caution about long-term PDE5 inhibitor exposure in young children. Prescribers citing STARTS-2 typically use it to justify closer monitoring rather than avoiding tadalafil entirely, because the underlying disease carries its own mortality risk.

Case Series and Registry Data

Beyond TEMPO, several published case series describe tadalafil use in children under 10. A 2014 report in Pediatric Cardiology described 12 children (median age 6.4 years) transitioned from sildenafil to tadalafil due to adherence difficulties; 10 of 12 maintained or improved their WHO functional class at 12 months [6]. A retrospective analysis published in the European Respiratory Journal (2018) found comparable hemodynamic outcomes when children were switched from three-times-daily sildenafil to once-daily tadalafil, with no new serious adverse events in the under-12 subgroup [7].

Dosing in Children Under 12: What Prescribers Use

No FDA-approved dosing exists for tadalafil in children under 12. Prescribers rely on weight-based extrapolation, pharmacokinetic modeling from TEMPO, and institutional protocols.

Weight-Based Dose Calculation

The standard off-label approach mirrors the TEMPO 1 mg/kg/day dose, with the following practical adjustments:

• Children weighing under 20 kg: 1 mg/kg/day, rounded to the nearest available compounded dose, typically administered as an oral suspension.
• Children weighing 20 to 40 kg: 20 mg/day, which corresponds to half the adult 40 mg Adcirca tablet or a compounded equivalent.
• Children weighing over 40 kg: up to 40 mg/day, aligned with the adult PAH dose.

Compounding is almost always necessary for young children because no commercial tadalafil suspension exists. Stability data for compounded tadalafil suspensions are limited; one study in the International Journal of Pharmaceutics described a 1 mg/mL suspension in Ora-Plus vehicle that remained stable for 91 days at refrigerated temperatures [8].

Pharmacokinetic Considerations

Tadalafil's half-life in adults is approximately 17.5 hours, supporting once-daily dosing [1]. Pediatric PK data from TEMPO suggested that clearance per kilogram is higher in younger children, meaning a weight-based dose may actually produce lower plasma exposures than the same mg/kg dose in an adult. This is one reason some centers start at 1 mg/kg/day and assess response before increasing [4].

Hepatic enzyme activity (CYP3A4 in particular) is developmentally regulated and generally higher per unit body weight in young children than in adults. This accelerated clearance should factor into dose selection, though formal PK models for children under 6 are not yet published in peer-reviewed form.

Safety Profile in the Under-12 Population

The adverse event profile of tadalafil in young children appears broadly similar to that in adults, with some age-specific considerations.

Cardiovascular Effects

Systemic hypotension is the primary concern. Tadalafil drops systemic vascular resistance modestly in healthy adults, but children with PAH often have right ventricular compromise that makes even small drops in systemic pressure clinically relevant. Blood pressure should be measured before the first dose and rechecked after the first week of therapy.

Concurrent use with other pulmonary vasodilators, particularly inhaled nitric oxide or intravenous epoprostenol, requires careful hemodynamic monitoring. The combination of a PDE5 inhibitor with a prostacyclin analogue may produce additive blood pressure reduction [9].

Growth and Development

No published data confirm or refute long-term effects of tadalafil on bone growth, puberty timing, or gonadal development in children under 12. The drug's mechanism does not involve sex hormone pathways, and PDE5 expression in bone is low, but multi-year exposure studies in pre-pubertal children simply do not exist. Pediatric endocrinology referral is reasonable in any child receiving tadalafil for more than 12 consecutive months.

Ocular and Auditory Signals

Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare but documented adverse event with PDE5 inhibitors in adults [1]. One case report in a 9-year-old with PAH described a transient visual disturbance that resolved after dose reduction [6]. Sudden hearing loss, another rare PDE5 inhibitor signal, has not been reported in published pediatric PAH series but warrants a counseling note.

Contraindications in Children

The contraindications mirror adult practice:

• Concurrent nitrate use of any form (risk of severe hypotension).
• Alpha-blockers combined with full-dose tadalafil.
• Severe hepatic impairment (Child-Pugh class C).
• Known hypersensitivity to tadalafil.

Regulatory and Prescriber Responsibilities

Off-Label Prescribing: Legal and Ethical Framework

Off-label prescribing is legal in the United States. The FDA permits physicians to prescribe approved drugs for unapproved indications, doses, or patient populations when clinical judgment supports it [2]. This standard applies fully to tadalafil in children under 12.

The ethical obligations are distinct from the legal ones. The American Academy of Pediatrics policy on off-label drug use states that prescribers should "use the best available evidence, discuss the off-label status with the patient's family, and document the rationale in the medical record" [10]. None of these steps are optional from a risk management standpoint.

Informed Consent Documentation

When tadalafil is prescribed off-label in a child under 12, the prescriber should document:

1. The diagnosis and severity (WHO functional class, hemodynamic data if catheterization has been performed).
2. The absence of an FDA-approved alternative that is clearly superior.
3. The specific dose chosen and the weight-based rationale.
4. The risks discussed with parents or guardians, including hypotension, rare visual and auditory events, and the absence of long-term pediatric safety data.
5. The monitoring plan and follow-up schedule.

Insurance coverage for off-label tadalafil in young children is inconsistent. Some payers require prior authorization with documentation of PAH diagnosis by right-heart catheterization, a procedure that carries its own risk in small children.

Specialist Oversight Requirements

General pediatricians should not initiate tadalafil in children under 12 without specialist input. Initiation belongs with a pediatric pulmonologist or pediatric cardiologist at a center with experience in pediatric PAH. The Pulmonary Hypertension Association and the American Thoracic Society both recommend multidisciplinary team management for pediatric PAH, and tadalafil initiation should occur in that context [9].

Monitoring Protocols for Children Under 12 on Tadalafil

Baseline Assessments

Before starting tadalafil, a standard workup includes:

• Echocardiography with estimation of right ventricular systolic pressure.
• Right-heart catheterization if the diagnosis has not been hemodynamically confirmed (vasoreactivity testing changes management in approximately 10% of pediatric PAH cases) [3].
• Liver function tests, given tadalafil's hepatic metabolism.
• Baseline blood pressure and heart rate.
• 6-minute walk test where age and developmental status permit (generally feasible from age 5 to 6 onward).

Follow-Up Schedule

The TEMPO protocol used 8-week and 24-week assessments as primary time points [4]. A practical follow-up schedule for off-label use in under-12s looks like:

• Week 2 to 4: blood pressure, heart rate, symptom check, parent-reported functional status.
• Month 3: echocardiography, liver function tests, weight-adjusted dose recalculation.
• Month 6: full reassessment including repeat catheterization if clinical deterioration.
• Annually: growth parameters, endocrinology review if pre-pubertal.

Dose recalculation at every visit is necessary because young children gain weight rapidly. A child who weighed 18 kg at initiation may weigh 22 kg six months later, pushing the appropriate dose from 18 mg/day to 22 mg/day (at 1 mg/kg/day). Missing this adjustment results in relative underdosing.

Alternatives and Combination Therapy

Tadalafil is rarely used as monotherapy in children with severe PAH. The 2022 European Society of Cardiology and European Respiratory Society guidelines on pulmonary hypertension recommend combination therapy for patients with intermediate or high risk [9]. In pediatric practice, tadalafil is often combined with:

• Endothelin receptor antagonists (bosentan or ambrisentan), both of which have some pediatric data.
• Prostacyclin analogues (inhaled iloprost or subcutaneous treprostinil) for high-risk presentations.

Bosentan has EMA approval for children above 1 year and FDA pediatric labeling for patients weighing above 10 kg, making it the most commonly initiated agent in young children. Tadalafil is often added when bosentan monotherapy produces an inadequate response, a sequence supported by adult combination trial data from AMBITION (N=500), which compared ambrisentan plus tadalafil versus monotherapy and found a 50% reduction in clinical failure events [11].

Applying AMBITION-derived conclusions to children under 12 is an extrapolation. No equivalent pediatric combination trial has been completed or registered as of early 2025.

The Evidence Gap: What Research Is Still Needed

The pediatric PAH field has published a pointed critique of the evidence base. As noted in a 2020 review in the American Journal of Respiratory and Critical Care Medicine, "the majority of treatment recommendations for pediatric pulmonary hypertension are derived from adult trials, with few adequately powered studies conducted exclusively in children" [12].

Specific gaps for tadalafil in under-12s include:

• No placebo-controlled RCT in children under 10 years.
• No long-term (beyond 3 years) open-label extension data in pre-school-age children.
• No formal PK study in children under 6 with population modeling of dose-exposure relationships.
• No data on cognitive or neurodevelopmental effects of chronic PDE5 inhibition in young children, given that PDE5 is expressed in brain tissue.

ClinicalTrials.gov lists no currently recruiting trials as of January 2025 that specifically address tadalafil dosing or safety in children under 12 as their primary endpoint. Registries such as TOPP continue to collect real-world data but are observational by design [3].